Analyst Ratings for IGM Biosciences
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 Wall Street analysts have provided ratings for IGM Biosciences (NASDAQ:IGMS), with 2 bullish and 3 indifferent ratings. The average 12-month price target for IGMS is $12.2, representing a 20.78% decrease from the previous target of $15.40. Analysts derive their ratings by researching company financials, attending calls and meetings, and communicating with insiders. The ratings are updated quarterly or after major company updates.
December 06, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IGM Biosciences received 2 bullish and 3 indifferent ratings from analysts, with an average price target of $12.2, down from $15.40. This suggests a bearish sentiment and a potential decrease in stock price in the short term.
The reduction in the average price target for IGMS by analysts indicates a bearish outlook, which could lead to a decrease in the stock price in the short term. Analyst ratings are influential as they are based on in-depth research and financial analysis, and a downward revision is often taken negatively by the market.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100